Synaptogenix Inc. (NASDAQ: SNPX)
$4.53
+0.1000 ( +2.26% ) 40.6K
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Market Data
Open
$4.53
Previous close
$4.43
Volume
40.6K
Market cap
$5.48M
Day range
$4.37 - $4.64
52 week range
$3.53 - $24.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jun 21, 2024 |
10-q | Quarterly Reports | 59 | May 15, 2024 |
4 | Insider transactions | 1 | Apr 10, 2024 |
4 | Insider transactions | 1 | Apr 10, 2024 |
4 | Insider transactions | 1 | Apr 10, 2024 |
4 | Insider transactions | 1 | Apr 10, 2024 |
8-k | 8K-related | 15 | Apr 04, 2024 |
10-k | Annual reports | 68 | Apr 01, 2024 |
8-k | 8K-related | 13 | Dec 21, 2023 |
10-q | Quarterly Reports | 53 | Nov 14, 2023 |